NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+21.58%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$2.01B
AUM Growth
+$2.01B
(+8.5%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-7.46%
Top 10 Holdings %
Top 10 Hldgs %
68.56%
Holding
39
New
1
Increased
6
Reduced
8
Closed
2
Top Buys
| 1 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$19.5M |
| 2 |
Viridian Therapeutics
VRDN
|
$8.76M |
| 3 |
Celldex Therapeutics
CLDX
|
$3.86M |
| 4 |
Merus
MRUS
|
$1.25M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$1.08M |
Top Sells
| 1 |
Apple
AAPL
|
$38.5M |
| 2 |
Salesforce
CRM
|
$30.5M |
| 3 |
Galecto
GLTO
|
$29.1M |
| 4 |
Vaxcyte
PCVX
|
$22.9M |
| 5 |
Edgewise Therapeutics
EWTX
|
$21.2M |
Sector Composition
| 1 | Healthcare | 57.87% |
| 2 | Financials | 10.69% |
| 3 | Technology | 10.64% |
| 4 | Consumer Discretionary | 2.64% |
| 5 | Communication Services | 2.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$526B
| $294M | 14.61% | 1,038,550 | – | – |
|
|
TEM
2
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $231M | 11.45% | 4,074,419 | – | – |
|
3
Brookfield
BN
$98.3B
| $186M | 9.22% | 3,491,230 -389,000 | -10% | -$20.7M |
|
|
4
Edgewise Therapeutics
EWTX
$1.51B
| $148M | 7.36% | 5,549,900 -794,530 | -13% | -$21.2M |
|
5
Corcept Therapeutics
CORT
$7.35B
| $112M | 5.54% | 2,411,362 | – | – |
|
6
ASML
ASML
$292B
| $111M | 5.52% | 133,336 | – | – |
|
|
7
Salesforce
CRM
$245B
| $101M | 5.01% | 368,560 -111,600 | -23% | -$30.5M |
|
|
8
Vaxcyte
PCVX
$4B
| $85.7M | 4.26% | 750,000 -200,000 | -21% | -$22.9M |
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $58.5M | 2.91% | 1,500,000 | – | – |
|
|
10
Viridian Therapeutics
VRDN
$1.5B
| $54.3M | 2.69% | 2,385,000 +385,000 | +19% | +$8.76M |
|
11
Alibaba
BABA
$322B
| $53.1M | 2.64% | 500,827 | – | – |
|
12
Insmed
INSM
$28.8B
| $52.9M | 2.63% | 724,666 -75,334 | -9% | -$5.5M |
|
13
Crinetics Pharmaceuticals
CRNX
$2.92B
| $51.1M | 2.54% | 1,000,000 | – | – |
|
14
Cable One
CABO
$909M
| $41.4M | 2.06% | 118,403 | – | – |
|
15
ArriVent BioPharma
AVBP
$776M
| $35.4M | 1.76% | 1,505,315 +5,315 | +0.4% | +$125K |
|
|
16
Merus
MRUS
$4.98B
| $35M | 1.74% | 700,000 +25,000 | +4% | +$1.25M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $34.4M | 1.71% | 490,000 | – | – |
|
|
18
Celldex Therapeutics
CLDX
$1.47B
| $32.8M | 1.63% | 963,663 +113,663 | +13% | +$3.86M |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $32.6M | 1.62% | 118,383 | – | – |
|
20
Pharvaris
PHVS
$1.39B
| $31.9M | 1.59% | 1,725,000 | – | – |
|
21
LanzaTech
LNZA
$49.1M
| $30.2M | 1.5% | 15,814,845 | – | – |
|
22
Brookfield Asset Management
BAM
$97B
| $29.7M | 1.47% | 627,207 | – | – |
|
|
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
| $28.5M | 1.41% | 1,544,000 | – | – |
|
24
Amicus Therapeutics
FOLD
$2.34B
| $26.7M | 1.33% | 2,500,000 | – | – |
|
25
Rocket Pharmaceuticals
RCKT
$354M
| $20.3M | 1.01% | 1,100,000 | – | – |
|